Risk for ILD/Pneumonitis Examined for Trastuzumab Deruxtecan

MONDAY, Aug. 22, 2022 -- For patients receiving trastuzumab deruxtecan (T-DXd) monotherapy, the incidence of adjudicated drug-related interstitial lung disease (ILD)/pneumonitis is 15.4 percent, according to a study published online Aug. 11 in ESMO...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news